Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141471 | 0.97 | KCNN4 (0.50) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 | |
| Bromide SCHEMBL11663273 | 0.95 | KCNN4 (0.48) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL9799860 | 0.89 | TAAR1 (0.45) | KCNN4TAAR1SLC6A2MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL14833269 | 0.87 | KCNN4 (0.41) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL7004942 | 0.86 | TAAR1 (0.52) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL3756447 | 0.85 | TAAR1 (0.52) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL13093815 | 0.84 | KIF11 (0.46) | KCNN4TAAR1KIF11MAPTSMN1; SMN2 | |
| SCHEMBL3406278 | 0.84 | KCNN4 (0.42) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL1151000 | 0.84 | KCNN4 (0.42) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL4230894 | 0.84 | KCNN4 (0.42) | KCNN4TAAR1SLC6A2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122450-A1 | SYNTHESIS OF A SUBSTITUTED FURAN | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-05-05 | — | — | US | claimed |
| US-9226941-B2 | Two-component cleaning and disinfecting system | UNION GAS CAPITAL PARTNERS, LLC | 2016-01-05 | — | — | US | claimed |
| US-20150320797-A1 | TWO-COMPONENT CLEANING AND DISINFECTING SYSTEM | UNION GAS CAPITAL PARTNERS, LLC | 2015-11-12 | — | — | US | claimed |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-113795239-B | Topical composition | 帝斯曼知识产权资产管理有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-111225900-A | 3, 4-disubstituted 3-cyclobutene-1, 2-diones and their use | 阿勒根公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-110831570-A | New use | 帝斯曼知识产权资产管理有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-105307647-B | Oral bactericidal composition for treating oral mucositis | 托马斯·贝尔纳多·加尔万冈萨雷斯 | 2019-06-28 | — | — | CN | disclosed |
| CN-101375826-A | Aqueous concentrates made of isethionate, taurate and betaine | CLARIANT INT LTD (CH) | 2009-03-04 | — | — | CN | disclosed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1022275-A1 | Process for purifying glycidyl (Meth) acrylate | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0105762-B1 | PROCESS FOR PRODUCING ANTHRAQUINONE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-03-09 | — | — | EP | disclosed |
| US-4519947-A | SULFONATING 1,4-DIAMINO-2,3-DIHALOGENO-ANTHRAQUINONE | SUMITOMO CHEMICAL CO., LTD. (JP) | 1985-05-28 | — | — | US | disclosed |
| EP-0105762-A2 | Process for producing anthraquinone compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-04-18 | — | — | EP | disclosed |
| US-3984605-A | Heat sensitive recording material containing decolorizing agent | MITSUBISHI PAPER MILLS, LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | SLC6A2 1318/4885KCNN4 714/4885TAAR1 1200/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | SLC6A2 1384/4885KCNN4 707/4885TAAR1 779/4885 |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | SLC6A2 4854/4885KCNN4 3757/4885TAAR1 2534/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | SLC6A2 4854/4885KCNN4 3757/4885TAAR1 2534/4885 |
| US-20160122450-A1 | SYNTHESIS OF A SUBSTITUTED FURAN | DCXR, PFAS, FUT6 | SLC6A2 1627/4885KCNN4 826/4885TAAR1 3296/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | SLC6A2 4854/4885KCNN4 3757/4885TAAR1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.